This Growth Stock Is Soaring. Is It a Buy?
Biotech company Axsome Therapeutics (NASDAQ: AXSM) did not perform well in the first six months of 2022, partly due to regulatory troubles. However, the drugmaker has rebounded tremendously since, and shares have doubled in the past three months.
What happened? Well, Axsome finally earned an important approval from regulators in the U.S. (more on that later). Furthermore, there are other things to cheer for about the company.
Should investors get in on Axsome Therapeutics while it is gaining momentum, or is now a good time for shareholders to cash in and leave?
Source Fool.com
